Quantcast

Latest Amgen Stories

2014-08-27 08:28:22

THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). Ivabradine is an oral drug that inhibits the I(f) current ("funny" current) in the sinoatrial node, the body's cardiac pacemaker.(1) Ivabradine works to slow the heart rate without negative effects on myocardial contractility or ventricular...

2014-08-25 16:29:28

IRVINE, Calif., Aug. 25, 2014 /PRNewswire/ -- Western Digital Corp. (NASDAQ: WDC) today announced that chief financial officer Tim Leyden, 62, is retiring after 24 years of distinguished service at the company. He is being succeeded by Olivier Leonetti, 50, who has served as vice president, finance at Amgen Inc. from 2011, after having previously spent 14 years in global finance leadership positions at Dell Inc. Leyden will remain with the company through January 2015 in a transition...

2014-08-21 12:29:02

CHICAGO, Aug. 21, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report)....

2014-08-18 16:28:18

Second Phase 3 Registrational Study Meets Primary and All Secondary Endpoints THOUSAND OAKS, Calif., Aug. 18, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. The primary endpoint was the proportion of patients with > 30 percent...

2014-08-13 16:26:02

THOUSAND OAKS, Calif., Aug. 13, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp(®) (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies due to the potential presence of cellulose and/or polyester particles observed in a small number of syringes during a routine quality examination. Lots 1042847, 1044141A, 1044141C, 1044141D, 1046891A, 1046891B,...

2014-08-13 16:25:38

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 13, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that the Phase 3 clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) did not meet its primary endpoint of improving overall survival (OS) (HR=0.975, 95 percent CI, 0.760, 1.249). The 315-patient, open-label study evaluated single-agent Kyprolis(®) (carfilzomib) for Injection...

2014-08-11 12:28:18

Twenty-five pharmaceutical companies being asked to adopt common principles re biosimilars on patient safety, lobbying and business partnerships. DETROIT, Aug. 11, 2014 /PRNewswire/ -- A coalition of 19 institutional investors representing $430 billion in assets commends Amgen and Novartis for support of a set of investor principles to guide corporate boards on policy and oversight responsibilities related to biosimilar activities. The principles, included in the coalition's Investor...

2014-08-04 08:27:13

Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 4, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its...

2014-07-28 12:27:31

DUBLIN, July 28, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly,...

2014-07-25 16:22:59

THOUSAND OAKS, Calif., July 25, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the third quarter of 2014. The dividend will be paid on Sept. 5, 2014, to all stockholders of record as of the close of business on Aug. 14, 2014. About AmgenAmgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related